Research Summary

Analyzed using Evidence Intelligence™

Tirzepatide improves diabetes management during Ramadan fasting

Last updated August 29, 2026

Key finding

Mean HbA1c significantly decreased from 7.6% (before Ramadan) to 6.5% (after Ramadan) (mean change: -1.1%; p <0.001).

This study evaluated the effects of Tirzepatide on glycemic control and body weight in Bangladeshi patients with Type 2 diabetes during Ramadan fasting, demonstrating significant improvements.

Quick read

Study at a glance

The essential study design details in one scan.

EvidenceScore™

Moderate

Study type

RCTs

Follow-up

Extended (5–20+ y)

Risk of bias

High Risk

Save research, organize studies, and quickly find important evidence again.

Plain-language summary

What this paper says

A plain-language read of the study’s main message and where it applies.

Study focus

This study evaluated the effects of Tirzepatide on glycemic control and body weight in Bangladeshi patients with Type 2 diabetes during Ramadan fasting, demonstrating significant improvements.

Clinical relevance

These findings are significant for managing Type 2 diabetes in populations observing Ramadan fasting. Effective glycemic control during fasting can help prevent complications associated with diabetes, making Tirzepatide a valuable option for patients during this period.

Keep in mind

Limited generalizability due to the specific population studied. Potential for unmeasured confounders affecting results. Short duration of follow-up post-Ramadan.

Published in

Journal Reference

Publication details and source links for this paper.

Muhammad HR, Shahjada S, Faria A, et al. Tirzepatide Improves Glycemic Control and Body Weight in Bangladeshi Patients with Type 2 Diabetes During Ramadan Fasting. Diabetes, Obesity & Metabolism. 2025;28(2):1508-1516. doi:10.1111/dom.70343

View DOI View on PubMed View on PMC

Main Effects

Mean HbA1c decreased from 7.6% to 6.5% (mean change: -1.1%; p <0.001).

Fasting plasma glucose reduced by -2 mmol/L (p <0.001).

Body weight decreased by 5.3 kg (6.3% of baseline; p <0.001).

Evidence network

How this study fits

Understand where this research contributes within the broader evidence network.

Evidence Context

This study contributes evidence to Tirzepatide and Body weight, Fasting Plasma Glucose (FPG), Gastrointestinal disorders incidence, and 2 more.

This study contributes evidence to

Intervention

Tirzepatide

Outcome

Body weight

Evidence topic

Glycemic Control

Primary intervention

Tirzepatide

Primary outcomes

Body weight
Fasting Plasma Glucose (FPG)
Gastrointestinal disorders incidence

Evidence topics

Glycemic Control Fasting Blood Glucose HbA1c Reduction Post-Meal and OGTT Glucose

Primary intervention

Tirzepatide

Primary outcomes

Body weight Fasting Plasma Glucose (FPG)Gastrointestinal disorders incidence

Evidence relationships

Intervention and outcome relationships this study adds to the evidence network.

Evidence pairs

Relationships

Evidence topics

contributes_evidence

Editorial context

Why this study matters

See why this paper is useful beyond its individual results.

Evidence network role

This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.

Moderate contributionModerate confidenceNetwork score: 72

Why it is useful

Contributes to 5 evidence relationships
Includes primary outcome data
Linked to 6 direct semantic evidence topics

Topic contributions

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Add related evidence to your Evidence Tracker

Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.

Primary evidence

Evidence relationship

GLP-1 Receptor Agonists and HbA1c

Related evidence

Evidence relationship

GLP-1 Receptor Agonists and Body Weight

Save evidence

Evidence relationship

GLP-1 Receptor Agonists and Fasting Glucose

Save evidence

Core evidence

Study findings

The primary outcomes reported in this study.

Body weight

Tirzepatide → Body weight

Evidence Intelligence™

EvidenceScore™: 83; Strong
ImpactScore™: 92; Very Positive
ConsistencyScore™: 100; consistent

Based on 13 studies

Add to Evidence Tracker

Fasting Plasma Glucose (FPG)

Tirzepatide → Fasting Plasma Glucose (FPG)

Evidence Intelligence™

EvidenceScore™: 77; Strong
ImpactScore™: 83; Positive
ConsistencyScore™: 67; generally_consistent

Based on 3 studies

Add to Evidence Tracker

Gastrointestinal disorders incidence

Tirzepatide → Gastrointestinal disorders incidence

Evidence Intelligence™

EvidenceScore™: 77; Strong
ImpactScore™: 50; Neutral
ConsistencyScore™: 100; consistent

Based on 4 studies

Add to Evidence Tracker

HbA1c

Tirzepatide → HbA1c

Evidence Intelligence™

EvidenceScore™: 83; Strong
ImpactScore™: 96; Very Positive
ConsistencyScore™: 100; consistent

Based on 14 studies

Add to Evidence Tracker

Postprandial blood glucose

Tirzepatide → Postprandial blood glucose

Evidence Intelligence™

EvidenceScore™: Emerging; Score 59 · Based on 1 study
ImpactScore™: 100; Very Positive
ConsistencyScore™: unclear; Not enough independent studies

Based on 1 study

Add to Evidence Tracker

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

Evidence Suggest

HbA1c levels significantly decreased by 1.1%.
Fasting plasma glucose reduced by 2 mmol/L.
Body weight decreased by 5.3 kg.

Who this applies to

Bangladeshi patients with Type 2 diabetes.
Individuals observing Ramadan fasting.

Keep in Mind

Results may not be applicable to non-Bangladeshi populations.
The study did not assess long-term effects beyond Ramadan.
Mild gastrointestinal events were reported, but no hypoglycemia occurred.

Between the Lines

Limited generalizability due to the specific population studied.
Potential for unmeasured confounders affecting results.
Short duration of follow-up post-Ramadan.

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

Connected Evidence

Explore related studies, evidence collections, and research questions.

Relationships organized using the Dediabetes Evidence Intelligence™ framework.

This study contributes to evidence on GLP-1 Receptor Agonists and HbA1c, GLP-1 Receptor Agonists and Body Weight.

Related evidence relationships

Explore in Evidence Explorer

This study contributes to the evidence on the following intervention-outcome relationships.

Medications

Detailed evidence

GLP-1 Receptor Agonists → HbA1c

Medications

Evidence Intelligence™

EvidenceScore™: 83; Strong
ImpactScore™: 96; Very Positive
ConsistencyScore™: 100; consistent

Based on 14 studies

View evidence

Medications

Detailed evidence

GLP-1 Receptor Agonists → Body Weight

Medications

Evidence Intelligence™

EvidenceScore™: 83; Strong
ImpactScore™: 92; Very Positive
ConsistencyScore™: 100; consistent

Based on 13 studies

View evidence

Included in these evidence collections

Curated evidence collections and hubs this study is part of.

GLP-1 Receptor Agonists Evidence Hub

All studies on GLP-1 Receptor Agonists

14 studies

intervention_hub

Contributes to GLP-1 Receptor Agonists evidence base.

HbA1c Evidence Hub

All studies measuring HbA1c

14 studies

outcome_hub

Measures HbA1c as a key outcome.

Body Weight Evidence Hub

All studies measuring Body Weight

13 studies

outcome_hub

Measures Body Weight as a key outcome.

Recent Diabetes Research

Latest published studies

recency_collection

Published within the last 2 years.

Explore more in Evidence Explorer

Jump to pre-filtered views in Evidence Explorer.

All studies on Tirzepatide and HbA1c

Intervention: TirzepatideOutcome: HbA1c

14 results

All studies on Tirzepatide and Body weight

Intervention: TirzepatideOutcome: Body weight

13 results

All studies on Tirzepatide

Intervention: Tirzepatide

14 results

All studies measuring HbA1c

Outcome: HbA1c

14 results

All studies measuring Body weight

Outcome: Body weight

13 results

Questions answered by this study

Generated from the study's connected evidence using Evidence Intelligence™.

Do GLP-1 Receptor Agonists lower HbA1c?

Strong Evidence

GLP-1 Receptor Agonists appear to lower HbA1c.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

1
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 83.5 | strong positive | ConsistencyScore™ Consistent | 1 study

Why this answer: This answer is based on 45 supporting studies with consistent results and a positive effect signal.

View Full Evidence

Do GLP-1 Receptor Agonists affect body weight?

Strong Evidence

GLP-1 Receptor Agonists may affect body weight.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

1
Body weight
EvidenceScore™ Strong | EvidenceScore™ 82.9 | strong positive | ConsistencyScore™ Consistent | 1 study

Why this answer: This answer is based on 43 supporting studies with consistent results and a positive effect signal.

View Full Evidence

Do GLP-1 Receptor Agonists improve fasting glucose?

Strong Evidence

GLP-1 Receptor Agonists may improve fasting glucose.

ConsistencyScore™: Results are generally consistent across studies.

Ranked evidence signals

1
Fasting Plasma Glucose (FPG)
EvidenceScore™ Strong | EvidenceScore™ 76.5 | moderate positive | ConsistencyScore™ Generally Consistent | 1 study

Why this answer: This answer is based on 18 supporting studies with generally consistent results and a positive effect signal.

View Full Evidence

Do GLP-1 Receptor Agonists improve postprandial and ogtt glucose?

Strong Evidence

GLP-1 Receptor Agonists may improve postprandial and ogtt glucose.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

1
Postprandial blood glucose
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on 10 supporting studies with consistent results and a positive effect signal.

View Full Evidence

Learn how Evidence Intelligence™ works

Next steps

Continue your research

Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.

Evidence topics

Follow the topics this study contributes to.

Glycemic Control Evidence Hub Fasting Blood Glucose Evidence Hub HbA1c Reduction Evidence Hub Post-Meal and OGTT Glucose Evidence Hub

Explore in Evidence Explorer

Open broader Evidence Explorer views for this relationship.

All studies on Tirzepatide and HbA1c All studies on Tirzepatide and Body weight All studies on Tirzepatide and Fasting Plasma Glucose (FPG)All studies on Tirzepatide and Postprandial blood glucose

Related research

Read related research summaries.

Tirzepatide may prevent type 2 diabetes in adults with obesity and prediabetes Tirzepatide improves glycemic control in early-onset type 2 diabetes Tirzepatide improves weight loss and cardiometabolic health Insulin glargine plus metformin and glimepiride improves glycemic control in type 2 diabetes.Tirzepatide improves cardiometabolic health in obesity.

No ads. No tracking.

Focused on evidence, not advertising.

Secure & private

Your data is always protected.

Always up to date

New studies added every day.